Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes?
about
Dietary fibre improves first-phase insulin secretion in overweight individualsSyntaxin 4 up-regulation increases efficiency of insulin release in pancreatic islets from humans with and without type 2 diabetes mellitusSignaling mechanisms of glucose-induced F-actin remodeling in pancreatic islet β cellsPrkar1a in the regulation of insulin secretion.Differential phosphorylation of RhoGDI mediates the distinct cycling of Cdc42 and Rac1 to regulate second-phase insulin secretion.Abnormal glucose homeostasis and pancreatic islet function in mice with inactivation of the Fem1b gene.Paracrinology of islets and the paracrinopathy of diabetes.Antidiabetic actions of an estrogen receptor β selective agonist.The immediate effects of a single bout of aerobic exercise on oral glucose tolerance across the glucose tolerance continuumCombination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucoseSnapin mediates incretin action and augments glucose-dependent insulin secretionFailing beta-cell adaptation in South Asian families with a high risk of type 2 diabetesIn vivo misfolding of proinsulin below the threshold of frank diabetes.CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients.Treatment with novel galactomannan derivative reduces 2-hour postprandial glucose excursions in individuals with type 2 diabetes treated with oral medications and/or insulin.Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice.Rp-cAMPS Prodrugs Reveal the cAMP Dependence of First-Phase Glucose-Stimulated Insulin Secretion.Hypothesis: one rate-limiting step controls the magnitude of both phases of glucose-stimulated insulin secretion.Synapsins I and II are not required for β-cell insulin secretion: granules must pool their own weight.Evolving insights regarding mechanisms for the inhibition of insulin release by norepinephrine and heterotrimeric G proteins.Changing metabolic signatures of amino acids and lipids during the prediabetic period in a pig model with impaired incretin function and reduced β-cell mass.The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes.Ca2+-secretion coupling is impaired in diabetic Goto Kakizaki ratsEffect of a daily supplement of soy protein on body composition and insulin secretion in postmenopausal women.Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?The ins and outs of secretion from pancreatic beta-cells: control of single-vesicle exo- and endocytosis.Identifying the targets of the amplifying pathway for insulin secretion in pancreatic beta-cells by kinetic modeling of granule exocytosis.Altered Plasma Profile of Antioxidant Proteins as an Early Correlate of Pancreatic β Cell Dysfunction.Involvement of a proapoptotic gene (BBC3) in islet injury mediated by cold preservation and rewarmingLiraglutide prevents fast weight gain and β-cell dysfunction in male catch-up growth ratsA 3-year follow-up study of β-cell function in patients with early-onset type 2 diabetesProtein Kinase Mitogen-activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Promotes Obesity-induced Hyperinsulinemia.Effects of prolonged fasting and sustained lipolysis on insulin secretion and insulin sensitivity in normal subjects.The sweeter side of ACE2: physiological evidence for a role in diabetes.Newcomer insulin secretory granules as a highly calcium-sensitive poolMechanisms of biphasic insulin-granule exocytosis - roles of the cytoskeleton, small GTPases and SNARE proteins.Modes of exocytosis and electrogenesis underlying canine biphasic insulin secretion.Assessment of β-cell function in human patients.Current role of short-term intensive insulin strategies in newly diagnosed type 2 diabetes.New insights concerning the molecular basis for defective glucoregulation in soluble adenylyl cyclase knockout mice
P2860
Q21560785-5BBC5784-A8BD-4D12-B7AC-7E1EFD201245Q24337806-2C8154A1-97C8-42EF-A775-6E7340B85F0EQ27026733-B5516318-33F2-4C85-9B64-1DEA1AB2792DQ33664930-4366428B-F52B-4904-99F5-CB82B38BC5BFQ33673544-E9879C05-1644-4B30-96B1-4AEAE7B8BEB9Q33925263-C7AE795B-9143-42DD-B57C-6722F4009C34Q34136529-22FBD004-6489-4274-A65E-43B01E9D727DQ34324370-68A536AC-C11C-4B92-AC16-36F84BE20B73Q34582349-7F5F4D00-3EE1-4C65-9CC5-3FF1588DC8A4Q34647835-CCC05405-F4CC-4681-A0A7-B5112CD27832Q34648996-4779018B-C54D-4B6F-84B0-2676C65EF648Q35121539-128D91A3-CC14-449F-9FFB-CA0471681075Q35123549-DE8481FD-15DF-4B09-8F42-A7EAA66BD663Q35130696-E320FFA7-B243-49FE-B707-1EFB7FB8B25BQ35682627-D094E730-8FBC-4B30-BBCE-5A5CEB55AF39Q35757097-769770B0-A48C-4596-A7FD-680F5741C2D3Q35794969-BF0738F1-429D-47F6-9F7F-969D181C3867Q35861860-11CEB3BF-5A4D-4811-AE48-880B4CE38B50Q35920736-C6E67980-BF75-47EA-81E5-AB78A93BFF4AQ36041923-6F9E96A7-CD3A-4252-820D-72653E199E64Q36109246-7FF43952-BCAF-42AD-8CE9-C7821DC2712BQ36182540-A34BD991-6A30-4A26-9371-448058C35B51Q36296022-5E38540D-D3E7-4D7F-A9D0-D45AE22D9307Q36384021-DA929897-D387-4B54-8349-D542363954FBQ36554243-53B3ED52-D034-47A3-BA45-D1E35767642DQ36786251-F50D0992-37C8-406C-B42C-D18E6BD27179Q36838909-331C3DD4-E224-45E1-A047-36791057A593Q36850046-4DFC12CB-0152-471B-B7F8-6AE553179C8FQ37070865-AC4DD797-8B45-4033-BEFA-9F75FA3A959DQ37071404-B7529BB5-C268-430B-8E80-81F3D5D29C34Q37107776-33B5FBAD-8192-438B-8662-401290C6DDF9Q37136815-B2390967-25A5-4477-A560-63036BF63C06Q37138709-B08B4D0F-14A0-4884-9FED-51ABF7A24E14Q37178255-5E9F06C0-45FD-493C-A7E8-541821EBEDD8Q37182979-CB9D86E8-D945-4B49-A5A0-0555F1E99A0FQ37417286-C76B2A38-B226-461E-B759-DB67F7565435Q37971646-76A1DBFE-64E6-48D0-858D-B225F1E95D2DQ38013003-0B28496F-66A8-49A3-9207-923B449F5644Q38095652-B67750C6-5B8F-4D80-89EB-120B903E9883Q38224884-8CE3210D-1402-4A26-8639-F4D402D4833D
P2860
Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes?
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Is reduced first-phase insulin ...... ed to develop type 2 diabetes?
@ast
Is reduced first-phase insulin ...... ed to develop type 2 diabetes?
@en
Is reduced first-phase insulin ...... ed to develop type 2 diabetes?
@nl
type
label
Is reduced first-phase insulin ...... ed to develop type 2 diabetes?
@ast
Is reduced first-phase insulin ...... ed to develop type 2 diabetes?
@en
Is reduced first-phase insulin ...... ed to develop type 2 diabetes?
@nl
prefLabel
Is reduced first-phase insulin ...... ed to develop type 2 diabetes?
@ast
Is reduced first-phase insulin ...... ed to develop type 2 diabetes?
@en
Is reduced first-phase insulin ...... ed to develop type 2 diabetes?
@nl
P1433
P1476
Is reduced first-phase insulin ...... ed to develop type 2 diabetes?
@en
P2093
John E Gerich
P304
P356
10.2337/DIABETES.51.2007.S117
P407
P478
51 Suppl 1
P577
2002-02-01T00:00:00Z